In the present study, we identified five genes (LDHA, PPAT, BFSP1, NR0B1, and PFKFB4) associated with the tumour immune microenvironment in HCC patient cohorts that may be applied as potential biomarkers of HCC immunotherapy outcome. This evidence concerns the gene NR0B1 and hepatocellular carcinoma.